163 related articles for article (PubMed ID: 12740913)
1. EBV-encoded EBNA-5 associates with P14ARF in extranucleolar inclusions and prolongs the survival of P14ARF-expressing cells.
Kashuba E; Mattsson K; Pokrovskaja K; Kiss C; Protopopova M; Ehlin-Henriksson B; Klein G; Szekely L
Int J Cancer; 2003 Jul; 105(5):644-53. PubMed ID: 12740913
[TBL] [Abstract][Full Text] [Related]
2. p14ARF induces the relocation of HDM2 and p53 to extranucleolar sites that are targeted by PML bodies and proteasomes.
Kashuba E; Mattsson K; Klein G; Szekely L
Mol Cancer; 2003 Mar; 2():18. PubMed ID: 12685933
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibitor induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5.
Pokrovskaja K; Mattsson K; Kashuba E; Klein G; Szekely L
J Gen Virol; 2001 Feb; 82(Pt 2):345-358. PubMed ID: 11161273
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus-encoded EBNA-5 forms trimolecular protein complexes with MDM2 and p53 and inhibits the transactivating function of p53.
Kashuba E; Yurchenko M; Yenamandra SP; Snopok B; Szekely L; Bercovich B; Ciechanover A; Klein G
Int J Cancer; 2011 Feb; 128(4):817-25. PubMed ID: 20473904
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus-encoded EBNA-5 binds to Epstein-Barr virus-induced Fte1/S3a protein.
Kashuba E; Yurchenko M; Szirak K; Stahl J; Klein G; Szekely L
Exp Cell Res; 2005 Feb; 303(1):47-55. PubMed ID: 15572026
[TBL] [Abstract][Full Text] [Related]
6. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo.
Xirodimas D; Saville MK; Edling C; Lane DP; Laín S
Oncogene; 2001 Aug; 20(36):4972-83. PubMed ID: 11526482
[TBL] [Abstract][Full Text] [Related]
7. Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways.
Zhao L; Samuels T; Winckler S; Korgaonkar C; Tompkins V; Horne MC; Quelle DE
Mol Cancer Res; 2003 Jan; 1(3):195-206. PubMed ID: 12556559
[TBL] [Abstract][Full Text] [Related]
8. PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein.
Stuber G; Flaberg E; Petranyi G; Otvös R; Rökaeus N; Kashuba E; Wiman KG; Klein G; Szekely L
Mol Cancer; 2009 Mar; 8():23. PubMed ID: 19323829
[TBL] [Abstract][Full Text] [Related]
9. Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage.
Joseph TW; Zaika A; Moll UM
FASEB J; 2003 Sep; 17(12):1622-30. PubMed ID: 12958168
[TBL] [Abstract][Full Text] [Related]
10. The MDM2-p53 interaction.
Moll UM; Petrenko O
Mol Cancer Res; 2003 Dec; 1(14):1001-8. PubMed ID: 14707283
[TBL] [Abstract][Full Text] [Related]
11. Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus.
Llanos S; Clark PA; Rowe J; Peters G
Nat Cell Biol; 2001 May; 3(5):445-52. PubMed ID: 11331871
[TBL] [Abstract][Full Text] [Related]
12. Sumoylation induced by the Arf tumor suppressor: a p53-independent function.
Tago K; Chiocca S; Sherr CJ
Proc Natl Acad Sci U S A; 2005 May; 102(21):7689-94. PubMed ID: 15897463
[TBL] [Abstract][Full Text] [Related]
13. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1.
Asher G; Lotem J; Sachs L; Kahana C; Shaul Y
Proc Natl Acad Sci U S A; 2002 Oct; 99(20):13125-30. PubMed ID: 12232053
[TBL] [Abstract][Full Text] [Related]
14. The Epstein-Barr virus EBNA-LP protein preferentially coactivates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter.
Peng R; Moses SC; Tan J; Kremmer E; Ling PD
J Virol; 2005 Apr; 79(7):4492-505. PubMed ID: 15767449
[TBL] [Abstract][Full Text] [Related]
15. Nucleolar p14(ARF) overexpression in Reed-Sternberg cells in Hodgkin's lymphoma: absence of p14(ARF)/Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts.
García JF; Villuendas R; Sánchez-Beato M; Sánchez-Aguilera A; Sánchez L; Prieto I; Piris MA
Am J Pathol; 2002 Feb; 160(2):569-78. PubMed ID: 11839577
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus EBNA3 proteins bind to the C8/alpha7 subunit of the 20S proteasome and are degraded by 20S proteasomes in vitro, but are very stable in latently infected B cells.
Touitou R; O'Nions J; Heaney J; Allday MJ
J Gen Virol; 2005 May; 86(Pt 5):1269-1277. PubMed ID: 15831937
[TBL] [Abstract][Full Text] [Related]
17. p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2.
Vestey SB; Sen C; Calder CJ; Perks CM; Pignatelli M; Winters ZE
Breast Cancer Res; 2004; 6(5):R571-85. PubMed ID: 15318938
[TBL] [Abstract][Full Text] [Related]
18. Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy.
Wesierska-Gadek J; Schloffer D; Kotala V; Horky M
Int J Cancer; 2002 Sep; 101(2):128-36. PubMed ID: 12209989
[TBL] [Abstract][Full Text] [Related]
19. Supramolecular complex formation between Rad6 and proteins of the p53 pathway during DNA damage-induced response.
Lyakhovich A; Shekhar MP
Mol Cell Biol; 2003 Apr; 23(7):2463-75. PubMed ID: 12640129
[TBL] [Abstract][Full Text] [Related]
20. B cell phenotype-dependent expression of the Epstein-Barr virus nuclear antigens EBNA-2 to EBNA-6: studies with somatic cell hybrids.
Contreras-Brodin BA; Anvret M; Imreh S; Altiok E; Klein G; Masucci MG
J Gen Virol; 1991 Dec; 72 ( Pt 12)():3025-33. PubMed ID: 1662694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
